Exscientia Signs AI Drug Discovery Collaboration with Merck KGaA to Discover Novel Small Molecule Drug Candidates
Shots:
- Exscientia will receive $20M up front & ~$674M upon achievement of development, regulatory, and sales-based milestones for all 3 initial programs along with royalties on product sales if Merck KGaA commercializes a therapeutic from one of the initial targets of the collaboration
- The collaboration will use Exscientia’s AI-driven precision drug design and discovery capabilities and Merck KGaA’s disease expertise in oncology and neuroinflammation, clinical development capabilities, and global footprint to discover novel small molecule drug candidates
- Both companies will identify additional targets in oncology and immunology or other mutually agreed disease areas
Ref: Businesswire | Image: Merck KGaA
Related News:- Dewpoint Therapeutics Collaborated with Novo Nordisk to Identify Small Molecule Drugs for Insulin Resistance and Diabetes Progression
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
